Simu Liu Joins Elevate Festival 2025 Lineup: Canada's National Tech Festival Returns with Global AI Leaders, Startup Open House, and Investor Opportunities.
ByAinvest
Thursday, Sep 11, 2025 9:03 am ET1min read
ATHA--
The reverse stock split aims to increase the price per share, comply with Nasdaq's $1.00 minimum bid price requirement, and potentially improve the marketability and liquidity of Athira's common stock. As of the effective date, every ten shares of Athira's issued and outstanding common stock will be combined into one share, reducing the total number of authorized shares from 900,000,000 to 90,000,000. The par value per share will remain unchanged at $0.0001. Proportional adjustments will be made to outstanding options, restricted stock units, and shares authorized under equity incentive plans.
Athira's transfer agent, Computershare Inc., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares in book-entry form are not required to take any action to receive post-split shares. Those holding shares in brokerage accounts or in "street name" will have their positions automatically adjusted.
Athira Pharma's reverse stock split is part of its broader strategy to attract a broader range of investors and generate greater interest in the company. However, it is important to note that the intended effects of the reverse stock split, including the potential increase in the price of the company's common stock and its ability to maintain its listing on the Nasdaq Capital Market, are subject to a number of risks and uncertainties [1].
For more information about Athira Pharma's reverse stock split, investors can refer to the company's definitive proxy statement filed with the Securities and Exchange Commission on April 14, 2025, available at www.sec.gov.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. For more information, visit www.athira.com.
Athira Pharma announced a 10-for-1 reverse stock split to increase the price per share, comply with Nasdaq's $1.00 minimum bid price requirement, and potentially improve marketability and liquidity. The split will be effective on September 17, 2025, and trading will begin on September 18, 2025. The par value per share will remain unchanged at $0.0001, and adjustments will be made to outstanding options and restricted stock units.
Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, has announced a 10-for-1 reverse stock split. The split is set to become effective on September 17, 2025, at 5:00 p.m. Eastern Time, with trading beginning on September 18, 2025, on the Nasdaq Capital Market under the existing ticker symbol "ATHA" [1].The reverse stock split aims to increase the price per share, comply with Nasdaq's $1.00 minimum bid price requirement, and potentially improve the marketability and liquidity of Athira's common stock. As of the effective date, every ten shares of Athira's issued and outstanding common stock will be combined into one share, reducing the total number of authorized shares from 900,000,000 to 90,000,000. The par value per share will remain unchanged at $0.0001. Proportional adjustments will be made to outstanding options, restricted stock units, and shares authorized under equity incentive plans.
Athira's transfer agent, Computershare Inc., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares in book-entry form are not required to take any action to receive post-split shares. Those holding shares in brokerage accounts or in "street name" will have their positions automatically adjusted.
Athira Pharma's reverse stock split is part of its broader strategy to attract a broader range of investors and generate greater interest in the company. However, it is important to note that the intended effects of the reverse stock split, including the potential increase in the price of the company's common stock and its ability to maintain its listing on the Nasdaq Capital Market, are subject to a number of risks and uncertainties [1].
For more information about Athira Pharma's reverse stock split, investors can refer to the company's definitive proxy statement filed with the Securities and Exchange Commission on April 14, 2025, available at www.sec.gov.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. For more information, visit www.athira.com.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet